RE: RE: NR This Morning, OHRI Tests to FollowHey Alan,
Let's call a spade a spade.....If things go poorly then it is going to be difficult for GAP going forward. However, keep in mind that Mr. Bryden has been behind this company since 2004, and has kept it funded when no one else would.
Also note that the tests at the Ottawa Hospital Research Institute are comparing:
--> GAP-107B8 in a liposomal formulation
--> GAP-107B8 in a targeted liposomal formulation
--> An enhanced variant of GAP-107B8 alone
--> An enhanced variant of GAP-107B8 in a liposomal formulation
Here are the results from their last test at OHRI before GAP-107B8 was placed into a liposomal formulation, and before coming out with the enhanced version:
Ottawa, Ontario/April 18, 2011 – PharmaGap Inc. (TSX-V: GAP; OTC.BB: PHRGF) (“PharmaGap” or “the Company”) today announced initial results from preclinical testing at the Ottawa Hospital Research Institute (“OHRI”). Initial results from this study are positive and provide evidence that a peptide formulation of PharmaGap’s lead cancer drug GAP-107B8 administered via the intraperitoneal route can reduce tumour burden (19%) and significantly suppress ascites formation (73%) relative to controls. The test was undertaken at OHRI in collaboration with Dr. Barbara Vanderhyden.
Dr. Vanderhyden, upon initial review of the data commented “The reduction in ascites volume is very interesting in its own right, because this is a notable cause of morbidity in women with ovarian cancer. There is currently no drug therapy that is effective against ovarian cancer-associated ascites accumulation. Paracentesis, the removal of abdominal ascites, is commonly used to alleviate symptoms and prolong survival of women with ovarian cancer. The presence of ascites in ovarian cancer has been reported to be an indicator of poor prognosis for survival and correlates with a significantly decreased 5-year survival rate (5% with ascites vs. 45% without ascites) among women with stage III or IV epithelial ovarian carcinoma.”
https://pharmagap.com/news/pr/04-18-2011.html